Posted by Michael Wonder on 18 Dec 2022
US FDA approves Vraylar (cariprazine) as an adjunctive treatment for major depressive disorder
16 December 2022 - Approval marks fourth indication for Vraylar, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder with an anti-depressant therapy, showing improvement in symptoms when compared to placebo and anti-depressant therapy.
AbbVie today announced that the US FDA has approved Vraylar (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults.
